Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?

Literature DB >> 31058256

Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?

Kali Zhou¹, Norah Terrault¹.

Abstract

Entities: Chemical Disease Gene Species

Year: 2018 PMID： 31058256 PMCID： PMC6497398 DOI： 10.21037/amj.2018.02.01

Source DB: PubMed Journal: AME Med J ISSN： 2520-0518

× No keyword cloud information.

18 in total

1. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.

Authors: Maureen M Jonas; Joan M Block; Barbara A Haber; Saul J Karpen; W Thomas London; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Kathleen B Schwarz; Brian J McMahon
Journal: Hepatology Date: 2010-10-01 Impact factor: 17.425

2. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors: Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal: JAMA Date: 2006-01-04 Impact factor: 56.272

3. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.

Authors: Chuen-Fei Chen; Wen-Chung Lee; Hwai-I Yang; Hung-Chuen Chang; Chin-Lan Jen; Uchenna H Iloeje; Jun Su; Chuhsing K Hsiao; Li-Yu Wang; San-Lin You; Sheng-Nan Lu; Chien-Jen Chen
Journal: Gastroenterology Date: 2011-06-22 Impact factor: 22.682

4. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

Authors: Henry L Y Chan; Chi Kuen Chan; Aric Josun Hui; Sing Chan; Fred Poordad; Ting-Tsung Chang; Philippe Mathurin; John F Flaherty; Lanjia Lin; Amy Corsa; Anuj Gaggar; G Mani Subramanian; John G McHutchison; George Lau; Sam Lee; Edward J Gane
Journal: Gastroenterology Date: 2014-01-23 Impact factor: 22.682

Review 3. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection.

Authors: Peter Schemmer; Patrizia Burra; Rey-Heng Hu; Christian M Hüber; Carmelo Loinaz; Keigo Machida; Arndt Vogel; Didier Samuel
Journal: Liver Int Date: 2021-12-20 Impact factor: 8.754

3 in total

Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?

1. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.

2. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

3. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.

4. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

5. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

6. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F.

7. The natural history of chronic hepatitis B virus infection.

8. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase.

9. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome.

10. Liver regeneration and aging: a current perspective.

Review 1. CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated.

Review 2. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B.

Review 3. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection.